Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Late-onset depression may signal increased risk for cognitive impairment, 

Dementia Risk Signals in Late-Onset Depression, With Lingfeng Xue, PhD

 occur after midlife, according to recent findings. The study identified deficits in fluid intelligence and visuospatial memory among individuals with late-onset depression, with these impairments partially mediating the association between depression onset and later dementia risk.

“These 2 [deficits] represent more…cognitive burden that involves multiple system[s],” Lingfeng Xue, PhD, from King’s College London, told 

“The factors behind it can be complicated, but these 2 deficits observed in late onset depression can say that the potential mechanism within late life depression can involve neurocognitive loss, or even…biological dysfunctions among people within mid to late age.”

The analysis evaluated adults aged ≥ 60 years using UK Biobank data with linked primary care records. Investigators categorized participants into depression-free controls, early-life depression, late-life depression with early onset, and late-life depression with late onset. At baseline, the team assessed cognitive performance across 5 domains and prospectively tracked incident dementia through clinical records until 2022.

Late-life depression with late onset was associated with worse performance in several cognitive domains compared with healthy controls, particularly fluid intelligence and visuospatial memory. Participants in this group also demonstrated worse fluid intelligence compared with individuals with late-life depression beginning earlier in life. During a median follow-up of 13.69 years, late-onset depression predicted incident dementia, with hazard ratios ranging from 1.41 to 1.52 across adjusted models. Deficits in fluid intelligence mediated 3.1% of the association (95% confidence interval [CI], 1.2% to 5.0%) and visuospatial memory mediated 1.4% (95% CI, 0.4% to 2.5%).

The results raise questions regarding earlier cognitive assessment in patients presenting with first-onset depression after midlife. Xue noted that cognitive testing may be feasible in routine care, particularly using low-cost screening tools, although broader implementation must consider resource constraints.

“When it comes to real world practice, it’s a matter of cost effectiveness,” he said. “In terms of cognitive testing, it might be easier…when it comes to paper and pen testing. It's cheaper and it's more accessible. Neuroimaging can be less accessible, and the findings can be harder to interpret, but in general, these are…recognized indicators or associates with the onset of late life depression. I would…definitely recommend it for both, but it really comes to cost effectiveness.”

The study also highlighted the potential influence of treatment. Although antidepressant exposure was not included in the primary analysis, Xue referenced additional work suggesting antidepressant use may modify cognitive outcomes and reduce dementia risk among individuals with late-life depression. He emphasized that treatment history represents an important factor requiring further investigation.

The trajectory of cognitive decline preceding dementia also informed interpretation of the findings. Gradual cognitive changes may begin years before clinical diagnosis.

“[Cognitive decline] can go back 15, even 20 years, before the actual [dementia] onset,” Xue said. “As this study suggests, it…warrants an earlier detection…of cognitive…or monitoring of cognitive trajectories in order to prevent later onset damage.”

Part 1 of the interview with Xue can be viewed

Xue L, Bocharova M, Young AH, Aarsland D. Late-onset depression predicts cognitive impairment and subsequent dementia among older adults with major depressive disorder: findings from UK Biobank and primary care linked data. 

. 2026;12(2):e88. Published 2026 Mar 10. 

Videos

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia Risk Signals in Late-Onset Depression, With Lingfeng Xue, PhD 

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Jessica Castle, MD, is the vice president of medical affairs at Dexcom.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: The G7 15-Day System and CGM Innovations at Dexcom, With Jessica Castle, MD

In this episode of Diabetes Dialogue, host Diana Isaacs, PharmD, is joined by Jessica Castle, MD, vice president of medical affairs at Dexcom, to discuss the company’s recent innovations in continuous glucose monitoring (CGM) and their clinical implications.

To open the episode, Castle outlines the launch of the Dexcom G7 15-day system, highlighting its extended wear duration, improved accuracy (MARD ~8%), and strong early adoption among adults. She notes ongoing efforts to optimize sensor longevity, particularly through adhesive enhancements, while acknowledging that pediatric expansion remains under evaluation due to unique wear challenges in children. Integration with automated insulin delivery systems continues to evolve, with further updates anticipated.

The discussion then shifts to Dexcom’s newly cleared Smart Basal feature, designed to address persistent clinical inertia in basal insulin titration for type 2 diabetes. Castle explains how clinician-defined parameters within the Dexcom Clarity platform enable automated daily dose adjustments based on CGM data, with the goal of minimizing both hyperglycemia and hypoglycemia. Early data presented at ATTD demonstrate significant improvements in mean glucose (>40 mg/dL reduction) and time in range (>20 percentage point increase), without increased hypoglycemia, underscoring both the safety and efficacy of this approach.

Isaacs and Castle also explore recent advancements in Dexcom’s digital ecosystem, including AI-driven meal detection and nutritional analysis within the Stelo and G7 platforms. These tools facilitate real-time behavioral insights, reinforcing CGM’s role as a powerful driver of lifestyle modification. Castle emphasizes the growing integration of artificial intelligence to deliver actionable, personalized feedback while maintaining clinical reliability.

Expanding beyond glycemic metrics, Castle reviews emerging real-world evidence supporting CGM use across diverse populations. Retrospective analyses presented at ATTD demonstrate substantial reductions in diabetic ketoacidosis (DKA), including >90% risk reduction in pediatric 

 following CGM initiation. Additional registry data in non-insulin-treated type 2 diabetes show meaningful A1C reductions (~0.6%) and associated weight loss, reinforcing the value of CGM beyond insulin-dependent populations. The conversation also highlights complementary benefits when CGM is used alongside newer pharmacotherapies, including GLP-1 receptor agonists and dual incretin agents.

The episode further addresses gaps in evidence, particularly in pregnancy. While CGM adoption is increasing and supported by growing data in gestational diabetes, Castle acknowledges limited evidence in preexisting type 2 diabetes during pregnancy. Ongoing studies, including the IMAGINE trial, aim to evaluate earlier CGM implementation and its potential to improve maternal and fetal outcomes, potentially reshaping current screening paradigms.

The discussion concludes with a forward-looking perspective on Dexcom’s innovation pipeline. Castle highlights Smart Basal and the G7 15-day system as near-term practice-changing tools, alongside continued advancements in sensor design, accuracy, and usability. Both speakers emphasize the expanding role of CGM as a foundational technology in diabetes management, supporting a more proactive, data-driven, and patient-centered approach to care across clinical settings.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others.

Podcasts

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March brought a steady stream of clinically significant updates in gastroenterology, spanning advances in inflammatory bowel disease (IBD), colorectal cancer screening, hepatic encephalopathy guidance, and persistent diagnostic challenges in everyday practice. From new clinical trial data to updated guideline recommendations, the month reflected both meaningful progress and ongoing gaps across the GI landscape.

New data from the AFFIRM trial highlighted the potential of subcutaneous risankizumab induction in Crohn’s disease, signaling a possible shift toward more flexible treatment approaches. At the same time, Colorectal Cancer Awareness Month placed renewed focus on screening, where, despite clear benefits and multiple available modalities, uptake continues to fall short of national goals.

The month also underscored the importance of clinical nuance, with expert insights into often-overlooked conditions like exocrine pancreatic insufficiency (EPI) and evolving strategies to reduce Clostridioides difficile recurrence. In parallel, updated guidance on hepatic encephalopathy offered clinicians a comprehensive framework for diagnosis and management.

Here’s a look at 5 key gastroenterology headlines from March 2026 you may have missed:

AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease

On March 2, 2026, AbbVie announced positive topline results from the phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (Skyrizi) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD). Study findings showed significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 12 compared to placebo. Of note, among patients with clinical response after 12 weeks of risankizumab SC induction treatment followed by 12 weeks of maintenance, 67% achieved CDAI clinical remission at week 24 and 57% achieved endoscopic response at week 24.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Can Crohn’s Induction Move Beyond Infusions? AFFIRM Trial Insights

Colorectal Cancer Screening in 2026: Progress, Gaps, and What Comes Next, With Renee Williams, MD

Despite decades of public health messaging and clear evidence supporting the benefits of screening, colorectal cancer screening rates in the United States remain below national targets. During the month of March, recognized as Colorectal Cancer Awareness Month, gastroenterologists emphasize both the progress made and the work that still lies ahead to improve early detection of colorectal cancer. Renee Williams, MD, explains the different colorectal cancer screening options available to patients, persistent barriers to uptake, and strategies to improve screening rates.

Colorectal Cancer Screening Explained: Colonoscopy, FIT, and What Comes Next

Diagnostic Challenges and Clinical Nuance of EPI, With Adam Kichler, DO

Greasy, foul-smelling stools and persistent bloating are often dismissed as routine gastrointestinal complaints, but they can signal a more overlooked issue. EPI remains a frequently missed contributor to gastrointestinal symptom burden, in part because its clinical presentation so often overlaps with more commonly diagnosed conditions. Adam Kichler, DO, a gastroenterologist and advanced endoscopist at Allegheny Health Network, explained why EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offered key insights on diagnosis and management.

Bridging the Gap in EPI Diagnosis and Management

ACG Issues New Hepatic Encephalopathy Guidelines For Diagnosis, Treatment, Nutrition, and Transplant, With Jasmohan Bajaj, MD, MS

A new American College of Gastroenterology guideline outlines 24 recommendations for the diagnosis, management, and prevention strategies for hepatic encephalopathy. Jasmohan Bajaj, MD, breaks down the key points from the document and what they mean for practice.

Vancomycin Taper Strategies to Prevent C Difficile Recurrence, With Emily McDonald, MD, MSc

 infection (CDI) affects an estimated 450,000 patients annually in the United States and carries substantial morbidity and healthcare costs. According to the US Centers for Disease Control and Prevention, about 1 in 9 people who get CDI will get it again in the subsequent 2-8 weeks. Emily McDonald, MD, MSc, explains the potential of an initial vancomycin taper regimen after standard therapy for reducing these recurrences.

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

5 Gastroenterology Headlines You Missed in March 2026

John Cijan He, MD, PhD, is a Professor of Medicine and Pharmacological Sciences and Chief of the Division of Nephrology at the Icahn School of Medicine at Mount Sinai.

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

Podocyte injury plays a central role as the shared mechanism driving proteinuria and progressive kidney dysfunction across both primary and secondary glomerular diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease.

Diabetic kidney disease affects approximately 30% to 40% of patients with diabetes, remaining a leading cause of kidney failure worldwide. FSGS accounts for an estimated 20% to 25% of adult nephrotic syndrome cases in the United States.

FSGS and diabetic kidney disease are among the most common glomerular conditions in which podocyte injury plays a central role. In both diseases, progressive podocyte loss is closely associated with worsening proteinuria and declining kidney function, underscoring the importance of these specialized cells in maintaining long-term renal stability.

In these conditions, the overall damage caused by podocyte injury has driven increasing attention toward understanding podocyte biology as both a marker of disease severity and a potential therapeutic target.

“Podocytes form the last barrier of the glomerular filtration system, and they are critical for maintaining that barrier,” John Cijan He, MD, PhD, Professor of Medicine and Pharmacological Sciences and Chief of the Division of Nephrology at the Icahn School of Medicine at Mount Sinai, shared in an interview with HCPLive. “If you lose podocytes, patients can develop proteinuria.”

Podocytes are highly specialized epithelial cells that wrap around glomerular capillaries and form interdigitating foot processes connected by slit diaphragms. They serve as the final selective barrier preventing the passage of proteins into the urine and are essential for maintaining normal glomerular function.

Furthermore, these cells are terminally differentiated, non-proliferating cells, meaning once they are injured or lost, they cannot be regenerated or replaced. This limitation plays a key role in the podocyte depletion hypothesis, which proposes that progressive loss of podocytes directly drives glomerulosclerosis, chronic proteinuria, and ultimately kidney failure.

“Unfortunately, we don’t currently have therapies that can restore podocytes. Another important point is that podocytes can detach or die, but they are what we call quiescent cells—they cannot regenerate or proliferate,” said He. “So, once podocytes are lost, that’s essentially it. The kidney has very limited ability to repair this injury.”

Since the loss of podocytes is irreversible, even modest injury can accumulate and accelerate disease progression over time. As a result, researchers are not only focused on treating the upstream causes of kidney disease, but are also trying to identify strategies to preserve podocyte integrity and slow their loss.

Additionally, He explains the ongoing effort to improve the measurement of podocyte injury. Currently, investigators are exploring new reproducible biomarkers, including urinary markers such as nephrin and other podocyte-associated proteins, to more early identify glomerular injury. Additional approaches include detection of podocyte fragments or intact podocytes shed into the urine, which may reflect ongoing structural damage within the glomerulus.

“Podometrics” is an emerging concept in this space, a method aimed at quantifying podocyte number and density as a way to more directly assess disease progression. Prior research has suggested that podocyte-based measurements may provide a less invasive window into glomerular health and could have utility in conditions beyond FSGS and diabetic kidney disease, including IgA nephropathy.

While proteinuria remains the dominant clinical marker, the field is gradually moving toward earlier and more precise methods of detecting glomerular injury, with the goal of improving risk stratification and enabling earlier intervention.

Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. 

https://doi.org/10.1152/physrev.00020.2002

Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. 

Puelles VG, Bertram JF. Understanding podocyte depletion in progressive kidney disease. 

https://doi.org/10.1038/s41581-018-0001-7

D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis. 

https://doi.org/10.1053/j.ajkd.2003.10.024

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. 

Wang G, et al. Urinary nephrin as a biomarker of podocyte injury in kidney disease. 

https://doi.org/10.1016/j.cca.2014.08.020

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

March 2026 featured a range of developments across psychiatry, including emerging psychedelic therapies, accelerated neuromodulation strategies, ethical considerations around artificial intelligence in mental health care, and new observational data linking metabolic therapies to psychiatric outcomes.

This month in review features the top 6 headlines in psychiatry.

Your Patient's New Therapist Is an AI. Now What?

Growing patient use of generative artificial intelligence tools for mental health support prompted discussion among psychiatrists and ethicists regarding safety, oversight, and clinical integration. Experts emphasized that patients are increasingly turning to conversational AI platforms for therapy-like interactions, raising concerns about accuracy, crisis management, and therapeutic boundaries. Clinicians highlighted the need for guidance on how to counsel patients using these tools, while acknowledging potential benefits such as increased accessibility and stigma reduction.

The discussion underscored that AI-based support may complement, but not replace, clinician-delivered psychotherapy, particularly for patients with complex psychiatric conditions or suicide risk.

 Richard Miller, MD (Elwyn Adult Behavioral Health), Hans Eriksson, MD, PhD (HMNC Brain Health), and Darlene King, MD (University of Texas Southwest Medical Center).

Latest Psychedelic Research in Depression

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

A phase 2b trial of inhaled mebufotenin (GH001) demonstrated rapid and clinically meaningful improvement in treatment-resistant depression (TRD) following a single-day individualized dosing regimen. Participants received up to 3 escalating doses within 1 treatment session, with symptom improvements observed within 1 week.

In a randomized cohort, remission by day 8 occurred in 57.5% of treated patients compared with none receiving placebo, with a large effect size and rapid onset of benefit. Investigators highlighted the potential scalability of a single-day psychedelic-based intervention relative to multi-session treatment models.

Psychedelic Therapy Matches Efficacy of Antidepressants in MDD, With Balázs Szigeti, PhD

A meta-analysis evaluating psychedelic-assisted therapy versus antidepressants in major depressive disorder (MDD) found comparable symptom improvement when accounting for trial blinding differences. Investigators noted that psychedelic-assisted therapy produced robust antidepressant effects but did not demonstrate superiority over open-label antidepressant treatment.

The findings suggested psychedelic therapy may expand treatment options rather than replace established pharmacotherapy, with further research needed to assess functional outcomes and real-world implementation.

Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days

Accelerated deep transcranial magnetic stimulation (dTMS) delivered over 6 days produced clinical outcomes comparable to standard multiweek treatment in MDD. A multisite noninferiority trial showed similar response and remission rates while shortening treatment duration.

Accelerated protocols also demonstrated faster symptom improvement and reduced time to remission, supporting their potential to improve access and adherence among patients with treatment-resistant depression.

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

Separate data comparing accelerated repetitive TMS (rTMS) to conventional once-daily treatment found both approaches produced significant reductions in depressive symptoms, with no statistically significant difference in efficacy.

Investigators noted that compressing treatment into a single week may improve adherence and reduce disruption to daily functioning, offering practical advantages for patients and clinics.

Semaglutide Linked to Lower Suicidality Risk in Diabetes, With Mark Taylor, MD

Real-world registry data suggested glucagon-like peptide-1 receptor agonists, including semaglutide, were associated with reduced suicidality, anxiety, and psychiatric-related sick leave among patients with type 2 diabetes. Investigators used a within-individual design comparing treatment and non-treatment periods for the same patients, strengthening causal inference.

The findings counter earlier safety concerns and highlight potential mental health benefits of metabolic therapies, although experts emphasized these agents should not be considered primary psychiatric treatments.

Articles

March 2026 psychiatry updates spanned AI-enabled mental health support, psychedelic interventions for depression, accelerated neuromodulation, and metabolic therapy–psychiatric outcome links. Clinicians and ethicists raised concerns about generative AI accuracy, crisis handling, and boundary-setting, while positioning AI as adjunctive rather than substitutive care. Psychedelic data included rapid TRD response to single-day inhaled mebufotenin and meta-analytic evidence suggesting efficacy comparable to antidepressants when blinding is considered. Noninferiority trials supported 1-week accelerated TMS protocols. Registry analyses associated GLP-1 receptor agonists with lower suicidality signals.

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

6 Psychiatry Headlines You Missed in March 2026 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on data from some of the most impactful trials presented at the American College of Cardiology 2026.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiomyopathy

Arrhythmia

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

ACC.26 Recap: 6 Practice-Changing Trials to Know

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

FDA News

Hepatology

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q1 2026 Recap: Top FDA Approvals

Catch up on the hematology headlines you missed in March 2026. 

Hematology

4 Hematology Headlines You Missed In March 2026

Amgen has announced positive topline results from their phase 3 trial comparing teprotumumab-trbw – administered via an on-body injector – to placebo.

News Report

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Thyroid Disorders

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Jane M. Grant-Kels, MD, is the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

This Q&A interview at AAD 2026 highlights health information technologies and AI tools used in dermatology practices.

Tips for AI and Health Information Technology in Dermatology Practice, With Jane M. Grant-Kels, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

In this episode, "Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis," the expert dermatologists explore the methodology behind matching adjusted indirect comparisons and their practical value in guiding evidence based treatment decisions for plaque psoriasis.

Video Series

Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis

This episode, titled "Analyzing IL-23 Inhibitors in Psoriasis," features panelists discussing the future of IL-23 targeted therapies and the practical considerations surrounding the anticipated shift toward oral treatment options in plaque psoriasis.

Analyzing IL-23 Inhibitors in Psoriasis

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 03/29

This Q&A interview with Grant-Kels highlights takeaways from her session on managing the needs of patients in dermatology practicers who are pregnant.

Advice for Evaluating Pregnant Patients in Dermatology, With Jane M. Grant-Kels, MD

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Latest News

Dementia Risk Signals in Late-Onset Depression, With Lingfeng Xue, PhD

Diabetes Dialogue: The G7 15-Day System and CGM Innovations at Dexcom, With Jessica Castle, MD

5 Gastroenterology Headlines You Missed in March 2026

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

6 Psychiatry Headlines You Missed in March 2026